The earnings call highlighted strong revenue growth, significant regulatory achievements, and promising developments in their pipeline, notably for YORVIPATH and TransCon CNP. While there were some challenges with currency impacts and increased SG&A expenses, the overall outlook remains positive with expectations of continued growth and financial improvements.

Company Guidance -

Q3 2025

During the Q2 2025 Ascendis Pharma earnings call, several key metrics and developments were discussed. YORVIPATH's revenue reached EUR 103 million, more than doubling from Q1, with over 1,500 prescribers writing prescriptions for around 3,100 unique patients in the U.S. The company also reported that more than 75 countries have commercial agreements for YORVIPATH. SKYTROFA's revenue was EUR 51 million, and the company noted continued growth in new patient starts. Total product revenue for the quarter was EUR 153.7 million, despite a negative foreign currency impact of EUR 7.6 million. Operating expenses were around EUR 180 million, with SG&A expenses rising to EUR 107.6 million. Ascendis is progressing towards cash flow positivity on a quarterly basis, with cash and cash equivalents totaling EUR 494 million at the end of the quarter.

Strong YORVIPATH Revenue Growth

YORVIPATH revenue in Q2 2025 reached EUR 103 million, more than doubling from Q1 despite currency headwinds. In the U.S., more than 1,500 prescribers wrote prescriptions for around 3,100 unique patients.

Regulatory Approvals and Progress

TransCon Growth Hormone received FDA approval for adult growth hormone deficiency, and TransCon PTH gained marketing authorization in the U.S., EU, and UK for hypoparathyroidism treatment.

TransCon CNP Priority Review

The FDA has granted priority review for TransCon CNP, recognizing its potential to improve the treatment of achondroplasia. The PDUFA date is November 30, 2025.

Financial Performance

Ascendis Pharma's total Q2 revenue was EUR 158 million, with strong product revenue driven by YORVIPATH and SKYTROFA. The company is nearing cash flow positivity.

Ascendis Pharma (ASND) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ASND Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 13, 2025	2025 (Q3)	-0.28 / -	-2.013	―	―	―
Aug 07, 2025	2025 (Q2)	-1.51 / -0.96	-2.236	57.07% (+1.28)	―
May 01, 2025	2025 (Q1)	-1.72 / -1.85	-2.692	31.30% (+0.84)	―
Feb 12, 2025	2024 (Q4)	-1.15 / -0.75	-1.802	58.44% (+1.05)	―
Nov 14, 2024	2024 (Q3)	-1.83 / -2.01	-3.149	36.06% (+1.14)	―
Sep 03, 2024	2024 (Q2)	-1.71 / -2.24	-2.528	11.57% (+0.29)	―
May 02, 2024	2024 (Q1)	-1.73 / -2.69	-2.317	-16.16% (-0.37)	―
Feb 07, 2024	2023 (Q4)	-2.12 / -1.80	-4.331	58.38% (+2.53)	―
Nov 07, 2023	2023 (Q3)	-2.78 / -3.15	-3.634	13.37% (+0.49)	―
Sep 05, 2023	2023 (Q2)	-2.95 / -2.53	-1.709	-47.95% (-0.82)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ASND Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$190.35	$191.49	+0.60%
May 01, 2025	$167.47	$172.06	+2.74%
Feb 12, 2025	$126.14	$142.49	+12.96%
Nov 14, 2024	$124.28	$126.51	+1.79%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Ascendis Pharma (ASND) report earnings?

Ascendis Pharma (ASND) is schdueled to report earning on Nov 13, 2025, TBA (Confirmed).

What is Ascendis Pharma (ASND) earnings time?

Ascendis Pharma (ASND) earnings time is at Nov 13, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is ASND EPS forecast?

ASND EPS forecast for the fiscal quarter 2025 (Q3) is -0.28.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing